Citius Oncology Inc (CTOR) Stock Price, Quote & News

Company Profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 967 6677

Address:

11 Commerce Drive, First Floor, Cranford, United States

SweStonk Feb. 6 at 5:45 PM

$CTOR $CTXR Dilution incoming. Every paid pump take this lower.

0 · Reply

BALUGA825 Feb. 6 at 5:28 PM

$CTXR $CTOR Today is the start ? Both entity connected. Discord Buzzword.

0 · Reply

XING851653619 Feb. 6 at 5:07 PM

$CTOR It'll happen soon, just like ANL did a few days ago. It will break through when nobody's watching. Now is the last and cheapest day.

0 · Reply

NYC100 Feb. 6 at 4:59 PM

$CTOR I hope so 🤞🤞

1 · Reply

SweStonk Feb. 6 at 3:03 PM

$CTOR lier..... They are not and last time you came they paid for a pump and nothing happened. Same this time. Still no money. Still no sales. Keep your bullshit to yourself

3 · Reply

XING851653619 Feb. 6 at 2:39 PM

$CTOR The company is about to announce some good news.

0 · Reply

SweStonk Feb. 6 at 2:11 PM

$CTOR Guess when Mazur took over you have three chances.

0 · Reply

NYC100 Feb. 6 at 12:00 AM

$CTOR $CTXR The stuck is holding even though everything is going down

1 · Reply

SweStonk Feb. 5 at 6:59 PM

$CTOR $CTXR Nothing will save this sadly.. ML = dead Halo = dead Lymphir = dead

0 · Reply

TwongStocks Feb. 3 at 3:51 PM

$CTOR New hire. Chad Lachapelle. Head of Sales at CTOR. He was originally hired by $CTXR in April 2024 to be the Head of Sales. But he left in June 2025 to join YMAB. Looks like he is back with CTOR.

1 · Reply

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTXR

Dec 23, 2025, 4:30 PM EST - 6 weeks ago

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTXR

Dec 10, 2025, 4:30 PM EST - 2 months ago

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTXR

Dec 9, 2025, 8:30 AM EST - 2 months ago

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTXR

Dec 4, 2025, 8:37 AM EST - 2 months ago

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

CTXR

Dec 1, 2025, 12:00 PM EST - 2 months ago

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

CTXR

Nov 25, 2025, 8:00 AM EST - 2 months ago

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

CTXR

Nov 21, 2025, 8:37 AM EST - 2 months ago

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

CTXR

Oct 20, 2025, 8:37 AM EDT - 3 months ago

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

Oct 17, 2025, 5:00 PM EDT - 4 months ago

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

CTXR

Oct 16, 2025, 8:47 AM EDT - 4 months ago

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

CTXR

Oct 7, 2025, 8:47 AM EDT - 4 months ago

Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe

Sep 10, 2025, 4:30 PM EDT - 5 months ago

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTXR

Sep 9, 2025, 8:30 AM EDT - 5 months ago

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTXR

Aug 22, 2025, 8:47 AM EDT - 6 months ago

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

CTXR

Aug 12, 2025, 4:30 PM EDT - 6 months ago

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Jul 17, 2025, 4:30 PM EDT - 7 months ago

Citius Oncology Announces Closing of $9.0 Million Public Offering

CTXR

Jul 16, 2025, 9:15 AM EDT - 7 months ago

Citius Oncology Announces Pricing of $9.0 Million Public Offering

CTXR

Jul 15, 2025, 8:32 AM EDT - 7 months ago

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

CTXR

Jun 17, 2025, 8:08 AM EDT - 8 months ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTXR

May 14, 2025, 4:30 PM EDT - 9 months ago

Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:37 AM EDT - 9 months ago

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTXR

Feb 14, 2025, 4:30 PM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTXR

Feb 14, 2025, 4:30 PM EST - 1 year ago

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Feb 6, 2025, 8:55 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTXR

Jan 7, 2025, 8:08 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTXR

Jan 6, 2025, 7:50 AM EST - 1 year ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTXR

Dec 27, 2024, 5:00 PM EST - 1 year ago

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

SweStonk Feb. 6 at 5:45 PM

$CTOR $CTXR Dilution incoming. Every paid pump take this lower.

0 · Reply

BALUGA825 Feb. 6 at 5:28 PM

$CTXR $CTOR Today is the start ? Both entity connected. Discord Buzzword.

0 · Reply

XING851653619 Feb. 6 at 5:07 PM

$CTOR It'll happen soon, just like ANL did a few days ago. It will break through when nobody's watching. Now is the last and cheapest day.

0 · Reply

NYC100 Feb. 6 at 4:59 PM

$CTOR I hope so 🤞🤞

1 · Reply

SweStonk Feb. 6 at 3:03 PM

$CTOR lier..... They are not and last time you came they paid for a pump and nothing happened. Same this time. Still no money. Still no sales. Keep your bullshit to yourself

3 · Reply

XING851653619 Feb. 6 at 2:39 PM

$CTOR The company is about to announce some good news.

0 · Reply

SweStonk Feb. 6 at 2:11 PM

$CTOR Guess when Mazur took over you have three chances.

0 · Reply

NYC100 Feb. 6 at 12:00 AM

$CTOR $CTXR The stuck is holding even though everything is going down

1 · Reply

SweStonk Feb. 5 at 6:59 PM

$CTOR $CTXR Nothing will save this sadly.. ML = dead Halo = dead Lymphir = dead

0 · Reply

TwongStocks Feb. 3 at 3:51 PM

$CTOR New hire. Chad Lachapelle. Head of Sales at CTOR. He was originally hired by $CTXR in April 2024 to be the Head of Sales. But he left in June 2025 to join YMAB. Looks like he is back with CTOR.

1 · Reply

TwongStocks Feb. 2 at 3:21 PM

Fiscal Q1 for $CTXR and $CTOR ended on Dec 31. 10-Q filing deadline is Monday Feb 16. Both CTXR and CTOR will have to file their respective 10-Qs within the next couple of weeks. Biggest item is Lymphir sales. CTOR reported that it launched in December. The upcoming 10-Q will report Lymphir's sales from launch through Dec 31. First full quarter of Lymphir sales (Jan-Mar 2026) will not be reported until the May 10-Q. Other items to look for: • Cash on hand as of Dec 31 and updated runway for both companies. In the Dec 10-K, both companies reported a runway through March 2026. • Will there be any updates on Mino-Lok or Halo-Lido? • Will they issue any 2026 guidance for Lymphir sales?

5 · Reply

TwongStocks Jan. 29 at 10:01 PM

$CTOR Definitive notice of shareholder consent filed. https://www.sec.gov/Archives/edgar/data/1851484/000121390026009524/ea0274187-def14c_citius.htm No major changes to the preliminary filing from Jan 20, which is explained in the quoted post. The approval of the warrants becomes effective February 18.

0 · Reply

kman1 Jan. 29 at 8:22 PM

$CTOR strange as he'll. Stock is running and no one says anything. This is rare as hens teeth.

0 · Reply

SweStonk Jan. 28 at 3:20 PM

$CTOR would be interesting to know how many over at $CTXR after being down 98%, bought Mazurs crap once again and invested in CTOR And if you did, how much are you down in CTOR? 50%?, 70%? Only one making money from CTXR and CTOR are Mazur and the shorts who are paying him heavily straight to his cayman account. Pssst, I have $5M to donate to charity but I dont have $5M or less to double down on the 98% loss on my 1 billion drug. Even tho you try to sell this shit to others? We all know if the pipeline was as you say it is you would have added on your position in a heart beat. But you and no one else in the management are and havent for YEARS because you know the scam will eventually crack...

1 · Reply

whathappenedtomyaccount Jan. 27 at 3:47 PM

$CTOR didn't they say they had manufactured stock on the shelves? what's the shelf life of that? is it just going to waste?

0 · Reply

SweStonk Jan. 23 at 10:49 PM

$CTOR You clearly dont know how to read. Argumenting with you is like talking to a wall. Go read business update from CTXR(parent company) and you will see they need more funding to commercialize lymphir and why Mazur is getting sued over his launch PR and later change to needing additional funding to commercialize. This is from the companies own business update. You should go read up before even thinking of making comments on a stock forum. You have facebook for the other stuff.... ML = dead Halo = dead Lymphir = not enough money and third in line treatment with better treatments making less than 100m/y(Lymphir with the debt = dead)

0 · Reply

NYC100 Jan. 23 at 10:38 PM

$CTOR you getting mad because of the truth 😂😂

1 · Reply

SweStonk Jan. 23 at 10:27 PM

$CTOR People like him is why Mazur can continue his scam. News headline is enough of DD to invest into a company... You should just hand me your money. Your portfolio will be gone within a year anyway.

0 · Reply

NYC100 Jan. 23 at 10:08 PM

$CTOR in the market and making money 💰 😂😂

1 · Reply

SweStonk Jan. 23 at 8:27 PM

$CTOR It is not an article but screenshot from CTXRs own business update released 23 december 2025 which you would understand if you actually read through it. Your DD seem to be some easy chatGPT prompts that go through news headlines and conclude information based on that alone. Goodluck investing in news headlines alone. That will really take you far 😂

0 · Reply

NYC100 Jan. 23 at 8:10 PM

$CTOR the article you put does not even have the name of the company does not even mention the stock 😂😂

0 · Reply

SweStonk Jan. 23 at 6:42 PM

$CTOR every research? Go read the business update released 23 dec..... Why do you think SP crashed after it?

0 · Reply

Market Cap	101.52M
Revenue (ttm)	0.00
Net Income (ttm)	-24.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.30

Volume	113,236
Avg Vol	498,742
Day's Range	N/A - N/A
Shares Out	88.28M
Stochastic %K	37%
Beta	3.09
Analysts	Strong Sell
Price Target	$6.00